Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
16 2월 2024 - 11:49PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month
of February 2024
Commission File
No. 001-38691
AURORA
CANNABIS INC.
(Translation of registrant's name into English)
2207 90B St. SW,
Edmonton, Alberta,
Canada T6X 1V8
(Address of principal executive office)
Indicate by check mark whether the
registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☐
Form 40-F ☒
INCORPORATION BY REFERENCE
This Form 6-K is hereby filed
and incorporated by reference in the registrant’s Registration Statement on Form F-10 (File No. 333-271479).
SUBMITTED HEREWITH
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AURORA CANNABIS INC.
/s/ Glen Ibbott
Glen Ibbott
Chief Financial Officer
Date: February 15, 2024
Exhibit 99.1
FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1 Name and Address of Company
Aurora Cannabis Inc. (“Aurora”
or the “Company”)
2207-90b Street SW
Edmonton, Alberta
T6X 1V8
Item 2 Date of Material Change
February
7, 2024
Item 3 News Release
A press release describing the material change was
disseminated by Aurora on February 8, 2024 through Cision PR Newswire and can be found on SEDAR+ at www.sedarplus.ca.
Item 4 Summary of Material Change
A wholly-owned subsidiary (“Aurora Sub”)
acquired the remaining approximately 90% equity interest that Aurora did not previously own of Indica Industries Pty Ltd (“MedReleaf
Australia”), a leading distributor of medical cannabis products, for an enterprise value of AUD$50 million, subject to customary
adjustments. Aurora paid AUD$9.45 million in cash with the balance of the purchase price satisfied by the issuance of common shares of
Aurora (the “Aurora Shares”).
Item 5 Full Description of Material Change
5.1 Full
Description of Material Change
On February 7, 2024, Aurora, through Aurora Sub, purchased
the remaining approximately 90% equity interest of MedReleaf Australia at a total enterprise value of AUD$50 million subject to customary
adjustments (the “Transaction”). As consideration, Aurora (i) issued the selling shareholders an aggregate of 69,489,941
Aurora Shares (the “Share Consideration”); and (ii) paid the selling shareholders AUD$9.45 million in cash (the “Cash
Consideration” and together with the Share Consideration, the “Consideration”), subject to customary adjustments
post-closing. Approximately 10% of the Consideration will be held in escrow to ensure certain obligations of the selling shareholders.
5.2 Disclosure
for Restructuring Transactions
Not applicable.
Item 6 Reliance on subsection 7.1(2) of National
Instrument 51-102
Not applicable.
Item 7 Omitted Information
Not applicable.
Item 8 Executive Officer
Further information regarding the matters described
in this report may be obtained from Ananth Krishnan, Vice President, Strategic Finance, who is knowledgeable about the details of the
Transaction and may be contacted at Ananth.krishnan@auroramj.com.
Item 9 Date of Report
February
15, 2024.
Aurora Cannabis (NASDAQ:ACB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Aurora Cannabis (NASDAQ:ACB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024